• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

良性前列腺梗阻的新兴治疗选择。

Emerging treatment options for benign prostatic obstruction.

机构信息

Bristol Urological Institute, Southmead Hospital, Bristol, UK.

出版信息

Curr Urol Rep. 2011 Aug;12(4):247-54. doi: 10.1007/s11934-011-0190-4.

DOI:10.1007/s11934-011-0190-4
PMID:21475952
Abstract

Benign prostatic obstruction (BPO) affects an increasing number of men with age. It can cause troublesome lower urinary tract symptoms, can have a negative impact on quality of life, and may be associated with significant morbidity. Currently available medication and surgical treatments are limited by adverse events, invasiveness, and patient compliance. This has driven research into the pathogenesis of benign prostatic hyperplasia and led to the development of novel pharmacological agents and minimally invasive therapeutic interventions. This review highlights emerging treatment options for BPO.

摘要

良性前列腺梗阻 (BPO) 会影响越来越多的老年男性。它会导致麻烦的下尿路症状，对生活质量产生负面影响，并且可能与重大发病率有关。目前可用的药物和手术治疗受到不良反应、侵袭性和患者依从性的限制。这推动了对良性前列腺增生发病机制的研究，并导致了新型药理制剂和微创治疗干预措施的发展。本文综述了 BPO 的新兴治疗选择。

相似文献

1
Emerging treatment options for benign prostatic obstruction.良性前列腺梗阻的新兴治疗选择。
Curr Urol Rep. 2011 Aug;12(4):247-54. doi: 10.1007/s11934-011-0190-4.
2
Prostatic stents and balloon dilatation.前列腺支架及球囊扩张术。
Br J Hosp Med. 1990 Jun;43(6):422-6.
3
Beyond medications: office-based procedures for benign prostatic obstruction.超越药物治疗：良性前列腺梗阻的基于诊室的治疗方法。
World J Urol. 2019 Jun;37(6):1023-1027. doi: 10.1007/s00345-019-02720-y. Epub 2019 Apr 29.
4
Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms.男性下尿路症状的新兴微创治疗选择。
Eur Urol. 2017 Dec;72(6):986-997. doi: 10.1016/j.eururo.2017.07.005. Epub 2017 Jul 19.
5
New and Emerging Technologies in Treatment of Lower Urinary Tract Symptoms From Benign Prostatic Hyperplasia.新型和新兴技术在治疗良性前列腺增生所致下尿路症状中的应用。
Sex Med Rev. 2019 Jul;7(3):491-498. doi: 10.1016/j.sxmr.2018.02.003. Epub 2018 Mar 30.
6
The management of prostatic obstruction with urethral stents.尿道支架治疗前列腺梗阻
Can J Urol. 2015 Oct;22 Suppl 1:75-81.
7
Lower urinary tract symptoms suggestive of benign prostatic obstruction--what's the long-term effectiveness of medical therapies?提示良性前列腺梗阻的下尿路症状——药物治疗的长期疗效如何？
Eur Urol. 2001;39 Suppl 3:20-5. doi: 10.1159/000052563.
8
Minimally invasive therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.良性前列腺增生继发下尿路症状的微创治疗
J Urol. 2007 Mar;177(3):820-1. doi: 10.1016/j.juro.2006.12.010.
9
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: design and implementation.提示良性前列腺梗阻的下尿路症状——Triumph研究：设计与实施
Eur Urol. 2001;39 Suppl 3:31-6. doi: 10.1159/000052565.
10
Prostatic stents for benign prostatic hyperplasia.用于良性前列腺增生的前列腺支架
J Long Term Eff Med Implants. 1997;7(1):101-14.

引用本文的文献

1
Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies.磁共振成像在良性前列腺增生叶分类中的应用：治疗策略研究的潜在表型生物标志物
AJR Am J Roentgenol. 2015 Sep;205(3):564-71. doi: 10.2214/AJR.14.13602.
2
The value of respective urodynamic parameters for evaluating the occurrence of complications linked to benign prostatic enlargement.各尿动力学参数在评估与良性前列腺增生相关并发症发生情况方面的价值。
Int Urol Nephrol. 2014 Sep;46(9):1761-8. doi: 10.1007/s11255-014-0722-1. Epub 2014 May 9.

本文引用的文献

1
Benign prostate hyperplasia: a review of the year's progress from bench to clinic.良性前列腺增生：从基础到临床的年度进展综述。
Curr Opin Urol. 2011 Jan;21(1):22-6. doi: 10.1097/mou.0b013e32834100dd.
2
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Ⅰ期和Ⅱ期研究表明，经直肠前列腺内注射 PRX302 治疗前列腺增生所致下尿路症状是安全有效的。
Eur Urol. 2011 May;59(5):747-54. doi: 10.1016/j.eururo.2010.11.024. Epub 2010 Nov 24.
3
Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
西洛多辛治疗疑似良性前列腺增生症男性下尿路症状：在欧洲进行的一项国际、随机、双盲、安慰剂和阳性对照临床试验结果。
Eur Urol. 2011 Mar;59(3):342-52. doi: 10.1016/j.eururo.2010.10.046. Epub 2010 Nov 10.
4
Transurethral resection of the prostate revisited and updated.经尿道前列腺切除术的再探讨与更新。
Curr Opin Urol. 2011 Jan;21(1):36-41. doi: 10.1097/MOU.0b013e3283411455.
5
New advances in benign prostatic hyperplasia: laser therapy.良性前列腺增生的新进展：激光治疗。
Curr Urol Rep. 2011 Feb;12(1):56-61. doi: 10.1007/s11934-010-0153-1.
6
Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms.他汀类药物的使用与良性前列腺增生和下尿路症状风险降低有关。
BJU Int. 2011 Feb;107(3):443-50. doi: 10.1111/j.1464-410X.2010.09598.x. Epub 2010 Aug 26.
7
Emerging drugs for the treatment of benign prostatic obstruction.治疗良性前列腺梗阻的新兴药物。
Expert Opin Emerg Drugs. 2010 Jun;15(2):159-74. doi: 10.1517/14728211003716459.
8
Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.维生素 D 受体激动剂针对良性前列腺增生的静态、动态和炎症成分。
Ann N Y Acad Sci. 2010 Apr;1193:146-52. doi: 10.1111/j.1749-6632.2009.05299.x.
9
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.一项安慰剂对照研究，旨在评估磷酸二酯酶 5 抑制剂 UK-369,003 治疗与临床良性前列腺增生相关的下尿路症状男性患者的疗效和安全性。
BJU Int. 2010 Sep;106(5):674-80. doi: 10.1111/j.1464-410X.2010.09204.x.
10
Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.黄体生成素释放激素拮抗剂曲普瑞林对人良性前列腺增生的体外抑制机制。
BJU Int. 2010 Nov;106(9):1382-8. doi: 10.1111/j.1464-410X.2010.09215.x.